Business, energy, technology, markets and global industry news from Business News Today

Bausch + Lomb Corporation

PharmaDeviceNews Bausch + Lomb Corporation
Bausch + Lomb’s Orphia AI-powered digital health platform is designed to support cataract patient education and reduce administrative pressure on ophthalmology practices. Representative image.
Medical Devices & Diagnostics

Bausch + Lomb is moving beyond eye-care products with an AI platform built around the patient journey

Bausch + Lomb’s Orphia brings AI to cataract education, but adoption will depend on workflow integration, validation, privacy and trust.

Read More
Glaucoma eye examination in progress as Bausch + Lomb discontinues BL1107 eye drops after the Phase 2 trial missed key visual function endpoints. Representative image.
Pharma & Biotech

Why Bausch + Lomb stopped its BL1107 neuroprotective glaucoma eye-drop program

Bausch + Lomb is dropping BL1107 eye drops after a Phase 2 glaucoma miss and redirecting the asset toward a geographic atrophy implant.

Read More
Representative image of a precision retina surgery procedure using advanced vitrectomy technology, reflecting Bausch + Lomb’s Bi-Blade+ launch in Europe and the growing focus on surgical control, fluidics stability and vitreoretinal workflow efficiency.
Medical Devices & Diagnostics

Can Bi-Blade+ strengthen Bausch + Lomb’s position in European retina surgery?

A faster cutter is only part of the story. Bausch + Lomb’s Bi-Blade+ launch tests whether surgical platform upgrades can drive loyalty.

Read More
Pharma & Biotech

Can Bausch + Lomb’s PreserVision AREDS3 shift the AMD supplement market beyond AREDS2 alone?

Bausch + Lomb’s PreserVision AREDS3 adds B vitamins to the AMD nutrition debate. Read what this could change for eye health and market strategy.

Read More